Clinical heterogeneity in families with multiple cases of inborn errors of immunity

Clinical heterogeneity in families with multiple cases of inborn errors of immunity

Copyright © 2024 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 259(2024) vom: 10. Feb., Seite 109896
1. Verfasser: Delavari, Samaneh (VerfasserIn)
Weitere Verfasser: Rasouli, Seyed Erfan, Fekrvand, Saba, Chavoshzade, Zahra, Mahdaviani, Seyed Alireza, Shirmast, Paniz, Sharafian, Samin, Sherkat, Roya, Momen, Tooba, Aleyasin, Soheila, Ahanchian, Hamid, Sadeghi-Shabestari, Mahnaz, Esmaeilzadeh, Hossein, Barzamini, Sahar, Tarighatmonfared, Fateme, Salehi, Helia, Esmaeili, Marzie, Marzani, Zahra, Fathi, Nazanin, Abolnezhadian, Farhad, Rad, Mina Kianmanesh, Saeedi-Boroujeni, Ali, Shirkani, Afshin, Bagheri, Zahra, Salami, Fereshte, Shad, Tannaz Moeini, Marzbali, Mahsa Yousefpour, Mojtahedi, Hanieh, Razavi, Azadehsadat, Tavakolinia, Naeimeh, Cheraghi, Taher, Tavakol, Marzieh, Shafiei, Alireza, Behniafard, Nasrin, Ebrahimi, Sare Sadat, Sepahi, Najmeh, Ghaneimoghadam, Amirhossein, Rezaei, Arezou, Kalantari, Arash, Abolhassani, Hassan, Rezaei, Nima
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Congenital inheritance Inborn errors of immunity Multiple cases Penetrance Primary immunodeficiency Adaptor Proteins, Signal Transducing Antigens, CD19 STK4 protein, human mehr... EC 2.7.1.11 Protein Serine-Threonine Kinases EC 2.7.11.1 Intracellular Signaling Peptides and Proteins
LEADER 01000caa a22002652 4500
001 NLM366749005
003 DE-627
005 20240410232359.0
007 cr uuu---uuuuu
008 240108s2024 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2024.109896  |2 doi 
028 5 2 |a pubmed24n1371.xml 
035 |a (DE-627)NLM366749005 
035 |a (NLM)38184287 
035 |a (PII)S1521-6616(24)00007-X 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Delavari, Samaneh  |e verfasserin  |4 aut 
245 1 0 |a Clinical heterogeneity in families with multiple cases of inborn errors of immunity 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 29.01.2024 
500 |a Date Revised 10.04.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2024 Elsevier Inc. All rights reserved. 
520 |a BACKGROUND: Inborn errors of immunity (IEI) are a diverse range of genetic immune system illnesses affecting the innate and/or adaptive immune systems. Variable expressivity and incomplete penetrance have been reported in IEI patients with similar clinical diagnoses or even the same genetic mutation 
520 |a METHODS: Among all recorded patients in the national IEI registry, 193 families with multiple cases have been recognized. Clinical, laboratory and genetic variability were compared between 451 patients with different IEI entities 
520 |a RESULTS: The diagnosis of the first children led to the earlier diagnosis, lower diagnostic delay, timely treatment and improved survival in the second children in the majority of IEI. The highest discordance in familial lymphoproliferation, autoimmunity and malignancy were respectively observed in STK4 deficiency, DNMT3B deficiency and ATM deficiency. Regarding immunological heterogeneity within a unique family with multiple cases of IEI, the highest discordance in CD3+, CD4+, CD19+, IgM and IgA levels was observed in syndromic combined immunodeficiencies (CID), while non-syndromic CID particularly severe combined immunodeficiency (SCID) manifested the highest discordance in IgG levels. Identification of the first ATM-deficient patient can lead to improved care and better survival in the next IEI children from the same family 
520 |a CONCLUSION: Intrafamilial heterogeneity in immunological and/or clinical features could be observed in families with multiple cases of IEI indicating the indisputable role of appropriate treatment and preventive environmental factors besides specific gene mutations in the variable observed penetrance or expressivity of the disease. This also emphasizes the importance of implementing genetic evaluation in all members of a family with a history of IEI even if there is no suspicion of an underlying IEI as other factors besides the underlying genetic defects might cause a milder phenotype or delay in presentation of clinical features. Thus, affected patients could be timely diagnosed and treated, and their quality of life and survival would improve 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Congenital inheritance 
650 4 |a Inborn errors of immunity 
650 4 |a Multiple cases 
650 4 |a Penetrance 
650 4 |a Primary immunodeficiency 
650 7 |a Adaptor Proteins, Signal Transducing  |2 NLM 
650 7 |a Antigens, CD19  |2 NLM 
650 7 |a STK4 protein, human  |2 NLM 
650 7 |a EC 2.7.1.11  |2 NLM 
650 7 |a Protein Serine-Threonine Kinases  |2 NLM 
650 7 |a EC 2.7.11.1  |2 NLM 
650 7 |a Intracellular Signaling Peptides and Proteins  |2 NLM 
700 1 |a Rasouli, Seyed Erfan  |e verfasserin  |4 aut 
700 1 |a Fekrvand, Saba  |e verfasserin  |4 aut 
700 1 |a Chavoshzade, Zahra  |e verfasserin  |4 aut 
700 1 |a Mahdaviani, Seyed Alireza  |e verfasserin  |4 aut 
700 1 |a Shirmast, Paniz  |e verfasserin  |4 aut 
700 1 |a Sharafian, Samin  |e verfasserin  |4 aut 
700 1 |a Sherkat, Roya  |e verfasserin  |4 aut 
700 1 |a Momen, Tooba  |e verfasserin  |4 aut 
700 1 |a Aleyasin, Soheila  |e verfasserin  |4 aut 
700 1 |a Ahanchian, Hamid  |e verfasserin  |4 aut 
700 1 |a Sadeghi-Shabestari, Mahnaz  |e verfasserin  |4 aut 
700 1 |a Esmaeilzadeh, Hossein  |e verfasserin  |4 aut 
700 1 |a Barzamini, Sahar  |e verfasserin  |4 aut 
700 1 |a Tarighatmonfared, Fateme  |e verfasserin  |4 aut 
700 1 |a Salehi, Helia  |e verfasserin  |4 aut 
700 1 |a Esmaeili, Marzie  |e verfasserin  |4 aut 
700 1 |a Marzani, Zahra  |e verfasserin  |4 aut 
700 1 |a Fathi, Nazanin  |e verfasserin  |4 aut 
700 1 |a Abolnezhadian, Farhad  |e verfasserin  |4 aut 
700 1 |a Rad, Mina Kianmanesh  |e verfasserin  |4 aut 
700 1 |a Saeedi-Boroujeni, Ali  |e verfasserin  |4 aut 
700 1 |a Shirkani, Afshin  |e verfasserin  |4 aut 
700 1 |a Bagheri, Zahra  |e verfasserin  |4 aut 
700 1 |a Salami, Fereshte  |e verfasserin  |4 aut 
700 1 |a Shad, Tannaz Moeini  |e verfasserin  |4 aut 
700 1 |a Marzbali, Mahsa Yousefpour  |e verfasserin  |4 aut 
700 1 |a Mojtahedi, Hanieh  |e verfasserin  |4 aut 
700 1 |a Razavi, Azadehsadat  |e verfasserin  |4 aut 
700 1 |a Tavakolinia, Naeimeh  |e verfasserin  |4 aut 
700 1 |a Cheraghi, Taher  |e verfasserin  |4 aut 
700 1 |a Tavakol, Marzieh  |e verfasserin  |4 aut 
700 1 |a Shafiei, Alireza  |e verfasserin  |4 aut 
700 1 |a Behniafard, Nasrin  |e verfasserin  |4 aut 
700 1 |a Ebrahimi, Sare Sadat  |e verfasserin  |4 aut 
700 1 |a Sepahi, Najmeh  |e verfasserin  |4 aut 
700 1 |a Ghaneimoghadam, Amirhossein  |e verfasserin  |4 aut 
700 1 |a Rezaei, Arezou  |e verfasserin  |4 aut 
700 1 |a Kalantari, Arash  |e verfasserin  |4 aut 
700 1 |a Abolhassani, Hassan  |e verfasserin  |4 aut 
700 1 |a Rezaei, Nima  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 259(2024) vom: 10. Feb., Seite 109896  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:259  |g year:2024  |g day:10  |g month:02  |g pages:109896 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2024.109896  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 259  |j 2024  |b 10  |c 02  |h 109896